Search Within

Eytan Moshe Stein

Formats
  1. Meeting Abstract (217)
  2. Journal Article (109)
  3. Review (18)
  4. Research Letter (14)
  5. Editorial (6)
  6. Book Section (3)
  7. Guidelines (2)
  8. Correspondence (1)
  9. Miscellaneous (1)
Groups
  1. Adult Leukemia (371)
  2. Center for Hematologic Malignancies (371)
  3. Department of Medicine (371)
  4. Hematologic Malignancies, Division of (371)
  5. Hematology-Oncology Fellows (111)
  6. GSK Faculty (92)

More Groups

People
  1. Martin Tallman (118)
  2. Ross Levine (75)
  3. Aaron Goldberg (43)
  4. Andriy Derkach (33)
  5. Jan Bewersdorf (33)
  6. Christopher Famulare (31)

More People

Years
  1. 2025 (20)
  2. 2024 (45)
  3. 2023 (49)
  4. 2022 (34)
  5. 2021 (31)
  6. 2020 (30)

More Years

Publications
  1. Blood (171)
  2. Journal of Clinical Oncology (23)
  3. Clinical Lymphoma, Myeloma and Leukemia (18)
  4. Haematologica (16)
  5. Blood Advances (14)
  6. Leukemia and Lymphoma (12)

More Publications

Publishers
  1. American Society of Hematology (186)
  2. Elsevier Inc. (32)
  3. American Society of Clinical Oncology (28)
  4. Ferrata Storti Foundation (16)
  5. Nature Publishing Group (15)
  6. Taylor & Francis Group (12)

More Publishers

Results (371)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Enasidenib plus azacitidine significantly improves complete remission and overall response compared with azacitidine alone in patients with newly diagnosed acute myeloid leukemia (AML) with isocitrate dehydrogenase 2 (IDH2) mutations: Interim phase II results from an ongoing, randomized study
    Meeting Abstract

    DiNardo, C. D.; Schuh, A. C.; Stein, E. M.; Montesinos Fernandez, P.; Wei, A.; De Botton, S.; Zeidan, A. M.; Fathi, A. T.; Quek, L.; Kantarjian, H. M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Molecular mechanisms mediating relapse following ivosidenib monotherapy in patients with IDH1-mutant relapsed or refractory acute myeloid leukemia
    Meeting Abstract

    Choe, S.; Wang, H.; DiNardo, C. D.; Stein, E. M.; De Botton, S.; Fathi, A. T.; Tallman, M. S.; Kantarjian, H. M.; Stone, R. M.; Quek, L.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Leukemia cell of origin influences p53 activity and therapeutic sensitivity via an Evi1-dependent mechanism
    Meeting Abstract

    Cai, S. F.; Chu, S.; Goldberg, A. D.; Parvin, S.; Koche, R.; Glass, J. L.; Stein, E. M.; Tallman, M. S.; Sen, F.; Famulare, C.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Precision medicine treatment in older AML: Results of beat AML master trial
    Meeting Abstract

    Burd, A.; Levine, R. L.; Ruppert, A. S.; Mims, A. S.; Borate, U.; Stein, E. M.; Patel, P. A.; Baer, M. R.; Stock, W.; Deininger, M. W.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Prevalence of inherited cancer predisposition mutations in a cohort of older AML patients enrolled on the beat AML master trial
    Meeting Abstract

    Borate, U.; Yang, F.; Press, R. D.; Pavlick, D.; Juckett, L.; Agarwal, A.; Burd, A.; Mims, A. S.; Stein, E. M.; Patel, P. A.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • RAS mutations are independently associated with decreased overall survival and event-free survival in patients with AML receiving induction chemotherapy
    Meeting Abstract

    Ball, B. J.; Hsu, M.; Devlin, S. M.; Famulare, C.; Cai, S. F.; Dunbar, A.; Epstein-Peterson, Z. D.; Menghrajani, K.; Glass, J. L.; Taylor, J.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • RAS mutations are independently associated with decreased overall survival and event-free survival in patients with AML receiving induction chemotherapy
    Meeting Abstract

    Ball, B. J.; Hsu, M.; Devlin, S. M.; Famulare, C.; Cai, S. F.; Dunbar, A.; Epstein-Peterson, Z. D.; Menghrajani, K.; Glass, J. L.; Taylor, J.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • How precision medicine is changing acute myeloid leukemia therapy
    Review

    Heuser, M.; Mina, A.; Stein, E. M.; Altman, J. K.
    American Society of Clinical Oncology Educational Book (2019)

    Fulltext@MSK | Save
  • Immunotherapy for acute myeloid leukemia: From allogeneic stem cell transplant to novel therapeutics
    Review

    Knorr, D. A.; Goldberg, A. D.; Stein, E. M.; Tallman, M. S.
    Leukemia and Lymphoma (2019)

    Fulltext@MSK | Save
  • Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia
    Journal Article

    Pollyea, D. A.; Tallman, M. S.; de Botton, S.; Kantarjian, H. M.; Collins, R.; Stein, A. S.; Frattini, M. G.; Xu, Q.; Tosolini, A.; See, W. L.; more...
    Leukemia (2019)

    Fulltext@MSK | Save